Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | HPGDS | O60760 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.39 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4739158 | 0.85 | RAB9A (0.59) | RAB9ANPC1MAPTLMNACYP2C9 | |
| SCHEMBL3221579 | 0.80 | CA1 (0.41) | RAB9ANPC1MAPTLMNACA12 | |
| SCHEMBL16951873 | 0.79 | NPC1 (0.41) | RAB9ANPC1MAPTLMNACYP2C9 | |
| SCHEMBL16960969 | 0.79 | VEGFA (0.41) | RAB9ANPC1KMT2ACA1CA2 | |
| SCHEMBL2813660 | 0.78 | ALDH1A1 (0.44) | MAPTCYP2C9KMT2AALDH1A1KDM4E | |
| SCHEMBL8718691 | 0.78 | MAOA (0.53) | RAB9ANPC1MAPTLMNACYP2C9 | |
| SCHEMBL2728977 | 0.78 | NPC1 (0.49) | RAB9ANPC1MAPTLMNACYP2C9 | |
| SCHEMBL16957982 | 0.77 | NPC1 (0.45) | RAB9ANPC1MAPTLMNACYP2C9 | |
| SCHEMBL16962064 | 0.77 | NPC1 (0.39) | RAB9ANPC1MAPTLMNACYP2C9 | |
| SCHEMBL23505962 | 0.76 | RAB9A (0.47) | RAB9ANPC1MAPTLMNACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2119717-B1 | 8-[3-amino-piperidin-1-yl]-xanthins, their production and utilisation as DPP IV inhibitors | BOEHRINGER INGELHEIM INT (DE) | 2018-01-17 | — | — | EP | claimed |
| US-8697868-B2 | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-04-15 | — | — | US | claimed |
| JP-4733058-B2 | — | — | 2011-07-27 | — | — | JP | claimed |
| US-7645763-B2 | dipeptidylpeptidase-IV inhibitors; antidiabetic agents, antiarthritic agents, obesity, allograft transplantation, and osteoporosis caused by calcitonin; 1,3-disubstituted-7-(2-butyn-1-yl)-8-(3-aminopiperidin-1-yl)-xanthine compounds | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-01-12 | — | — | US | claimed |
| EP-2119717-A1 | 8-[3-amino-piperidin-1-yl]-xanthins, their production and utilisation as DPP IV inhibitors | Boehringer Ingelheim International GmbH (DE) | 2009-11-18 | — | — | EP | claimed |
| US-20090137801-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-28 | — | — | US | claimed |
| EP-1758905-B1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINE, THE PRODUCTION THEREOF AND THE USE IN THE FORM OF A DDP-IV INHIBITOR | BOEHRINGER INGELHEIM INT (DE) | 2009-04-29 | — | — | EP | claimed |
| US-7501426-B2 | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-03-10 | — | — | US | claimed |
| EP-1720875-B1 | 8- [3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PRODUCTION THEREOF, AND THE USE OF THE SAME AS MEDICAMENTS | BOEHRINGER INGELHEIM INT (DE) | 2008-12-10 | — | — | EP | claimed |
| EP-1758905-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINE, THE PRODUCTION THEREOF AND THE USE IN THE FORM OF A DDP-IV INHIBITOR | Boehringer Ingelheim International GmbH (DE) | 2007-03-07 | — | — | EP | claimed |
| EP-1720875-A1 | 8- [3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PRODUCTION THEREOF, AND THE USE OF THE SAME AS MEDICAMENTS | Boehringer Ingelheim International GmbH (DE) | 2006-11-15 | — | — | EP | claimed |
| US-20050234108-A1 | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-10-20 | — | — | US | claimed |
| WO-2005085246-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINE, THE PRODUCTION THEREOF AND THE USE IN THE FORM OF A DPP INHIBITOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-09-15 | — | — | WO | claimed |
| WO-2005082906-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PRODUCTION THEREOF, AND THE USE OF THE SAME AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-09-09 | — | — | WO | claimed |
| US-20050187227-A1 | 8-[3-Amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical composition | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-08-25 | — | — | US | claimed |
| EP-2119717-B1 | 8-[3-amino-piperidin-1-yl]-xanthins, their production and utilisation as DPP IV inhibitors | BOEHRINGER INGELHEIM INT (DE) | 2018-01-17 | — | — | EP | disclosed |
| EP-2900645-A1 | 3-PHENYLISOXAZOLIN DERIVATIVES WITH HERBICIDAL ACTION | Bayer CropScience AG (DE) | 2015-08-05 | — | — | EP | disclosed |
| US-6136980-A | Method of preparing norbenzomorphane as an intermediate in the preparation of pharmaceutically useful benzomorphane derivatives, in particular (-)-(1R,5S,2\"R)-3'-hydroxy-2-(2-methoxypropyl)-5,9,9-trimethyl-6,7-benzo morphane | BOEHRINGER INGELHEIM KG (DE) | 2000-10-24 | — | — | US | disclosed |
| US-6054604-A | Method of preparing norbenzomorphane as an intermediate | BOEHRINGER INGELHEIM KG (DE) | 2000-04-25 | — | — | US | disclosed |
| US-5945535-A | Method of preparing norbenzomorphanes | BOEHRINGER INGELHEIM KG (DE) | 1999-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137801-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | DPP8, DPP4, DPP7 | RAB9A 2812/4885NPC1 1815/4885MAPT 295/4885 |
| US-20050234108-A1 | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions | DPP8, DPP4, DPP7 | RAB9A 2916/4885NPC1 1447/4885MAPT 330/4885 |
| US-20050187227-A1 | 8-[3-Amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical composition | DPP8, DPP4, DPP7 | RAB9A 2967/4885NPC1 2012/4885MAPT 340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.